These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38599047)

  • 1. Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature.
    van Olmen JP; Jacobs CF; Bartels SAL; Loo CE; Sanders J; Vrancken Peeters MTFD; Drukker CA; van Duijnhoven FH; Kok M
    Breast; 2024 Jun; 75():103726. PubMed ID: 38599047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients.
    Schipper RJ; de Bruijn A; Voogd AC; Bloemen JG; Van Riet YE; Vriens BEP; Smidt ML; Siesling S; van der Sangen MJC; Nieuwenhuijzen GAP
    Eur J Surg Oncol; 2021 Aug; 47(8):1928-1933. PubMed ID: 34030918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG).
    Skriver SK; Laenkholm AV; Rasmussen BB; Handler J; Grundtmann B; Tvedskov TF; Christiansen P; Knoop AS; Jensen MB; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):31-37. PubMed ID: 29168427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
    Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
    Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
    Whitworth P; Beitsch P; Mislowsky A; Pellicane JV; Nash C; Murray M; Lee LA; Dul CL; Rotkis M; Baron P; Stork-Sloots L; de Snoo FA; Beatty J
    Ann Surg Oncol; 2017 Mar; 24(3):669-675. PubMed ID: 27770345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
    Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
    PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
    Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
    Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer.
    Ragusi MA; Winter-Warnars GA; Wesseling J; Linn SC; Beets-Tan RG; van der Velden BH; Elias SG; Gilhuijs KG; Loo CE
    Br J Radiol; 2021 Jul; 94(1123):20201125. PubMed ID: 34142870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer.
    Morales Murillo S; Gasol Cudos A; Veas Rodriguez J; Canosa Morales C; Melé Olivé J; Vilardell Villellas F; Sanchez Guzman DR; Iglesias Martínez E; Salud Salvia A
    Breast; 2021 Apr; 56():35-41. PubMed ID: 33601299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locoregional and Overall Recurrence After Neaodjuvant Endocrine Therapy Versus Chemotherapy in Postmenopausal Women With Estrogen Receptor+ HER2- Breast Cancer.
    Wright JL; Saigal K; Reis IM; Zhao W; Takita C; Ambros T; Saeed AM; Sujoy V; Hurley J
    Am J Clin Oncol; 2017 Oct; 40(5):490-497. PubMed ID: 26017482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
    von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
    Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing Occult Nodal Disease Within a Clinically Node-Negative, Neoadjuvant Breast Cancer Population.
    Hammond JB; Scott DW; Kosiorek HE; Parnall TH; Gray RJ; Ernst BJ; Northfelt DW; McCullough AE; Ocal IT; Pockaj BA; Cronin PA
    Clin Breast Cancer; 2022 Feb; 22(2):186-190. PubMed ID: 34462208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
    Mohapatra M; Sarma YS
    J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
    Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
    van Dam PA; van Dam VC; Altintas S; Papadimitriou K; Rolfo C; Trinh XB
    Eur J Surg Oncol; 2016 Mar; 42(3):333-42. PubMed ID: 26776766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
    Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
    BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.